Progen Co., Ltd. (XKON:296160)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,545.00
-120.00 (-2.57%)
At close: May 14, 2026
Market Cap63.65B -27.9%
Revenue (ttm)450.00M +1,700.0%
Net Income-15.25B
EPS-3,307.00
Shares Out15.38M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume9,290
Average Volume14,654
Open4,665.00
Previous Close4,665.00
Day's Range4,320.00 - 4,820.00
52-Week Range4,040.00 - 9,970.00
Beta-1.10
RSI14.16
Earnings Daten/a

About Progen

Progen Co., Ltd., a biotechnology company, engages in platform-based drug discovery and development activities. The company’s NTIG platform technology is used for the development of anti-cancer and immune disease treatments. It develops PG-102 for the treatment of obesity with T2DM to control blood sugar, improve metabolic function, and reduce weight in the gastrointestinal tract and adipocytes. The company was founded in 1998 and is based in Seoul, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1998
Country South Korea
Stock Exchange Korea New Exchange
Ticker Symbol 296160
Full Company Profile